Dermatology最新文献

{"title":"Demographics, Comorbidity, Treatment, Healthcare Resource Utilization and Costs Analysis of Hidradenitis Suppurativa in Dubai.","authors":"Anwar Al Hammadi, Samir Hantirah, Ashraf Mohamed Reda, Mohamed Farghaly, Falk Bechara, Saad Ehab, Dayane Daou, Amal Masalmeh, Kumaresan Subramanyam, Badarinath Chickballapur Ramachandrachar, Ashok Natarajan","doi":"10.1159/000545025","DOIUrl":"https://doi.org/10.1159/000545025","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic, inflammatory, and debilitating skin disorder with a substantial disease burden. Currently, there is a dearth of information regarding healthcare resource utilization (HCRU) and treatment patterns for patients with HS in Dubai. A better understanding of disease demographics and patient characteristics are necessary for reducing the healthcare costs. The current study evaluated the disease burden, treatment patterns, HCRU, and associated costs in patients with hidradenitis suppurativa, in Dubai, United Arab Emirates (UAE).</p><p><strong>Methods: </strong>This secondary, longitudinal, retrospective, single-cohort study was conducted from 01 January 2014 to 31 December 2021. Dubai Real-World Claims Database (DRWD) was used for patients' information. Study included patients with first diagnosis claim during the index period and had continuous enrolment. Patients who did not have continuous enrolment were excluded from the study. Study population was identified based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code L73.2. Patients' demographics, common comorbidities, treatment patterns, specialty analysis, HCRU, and in patient length of stay were investigated.</p><p><strong>Results: </strong>The study included 13,180 patients (median age: 37 years), with similar gender distribution (male: 50.4%; female: 49.6%). The overall reported cases of HS (2015-2021) was in the range of 1,350 to 3,719. Type 2 diabetes mellitus was the most common comorbidity (59.0%). Topical and systemic antibiotics were most frequently prescribed medications (79.6%), followed by systemic and topical anti-acne medications (27.7%), and non-steroidal anti-inflammatory drugs (27.2%). Overall HCRU and associated costs increased by 76.9% from 12-month pre-index period to 12-month post-index period. Disease-specific median healthcare costs contributed largely (79.5%) to the overall healthcare costs. In the post-index period, contribution of disease-specific median healthcare costs to all-cause median healthcare costs was highest for diagnosis related group (DRG) (97.9%), followed by consumables (88.4%), procedures (37.5%), services (27.6), and medications (25.4%).</p><p><strong>Conclusion: </strong>HS is well-documented disease in Dubai claims data and is associated with significant morbidity and healthcare costs. This sheds light on the high burden of HS and should trigger increased awareness as well as new disease management interventions. Newer therapies such as biologics should play a role in the management of HS in the UAE.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparing for Polygenic Risk Scores in the clinic: an accessible guide to reading and interpreting GWAS.","authors":"Faith Simmonds, Gregor B E Jemec, Lynn Petukhova","doi":"10.1159/000547616","DOIUrl":"https://doi.org/10.1159/000547616","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI for Distinguishing Perianal Hidradenitis Suppurativa From Fistulizing Crohn Disease.","authors":"Mika Yamanaka-Takaichi, Mariana Yalon, Edward V Loftus, Anna B Grimaldo, Austin Todd, David Anthony Wetter, Hamid R Tizhoosh, Eric J Dozois, Afsaneh Alavi, Eric C Ehman","doi":"10.1159/000547570","DOIUrl":"https://doi.org/10.1159/000547570","url":null,"abstract":"<p><strong>Introduction: </strong>Both hidradenitis suppurativa (HS) and Crohn disease (CD) are characterized by suppuration and granulomatous inflammation, which may result in formation of tunnels, sinus tracts, or fistulas. We sought to determine the differences in characteristics of fistulizing perianal CD vs perianal HS on magnetic resonance imaging (MRI).</p><p><strong>Methods: </strong>This retrospective cohort study included patients diagnosed with CD, HS, or both diseases who underwent medical examination at Mayo Clinic between January 1, 1998, and July 31, 2021. We further selected patients who had documented perianal lesions and underwent pelvic MRI. Two abdominal radiologists blinded to clinical diagnosis reviewed the MR images for the presence or absence of 10 characteristics. For characteristics that differed significantly between patients with CD and HS, odds ratios were calculated. A radiomics-based MRI scoring system was constructed according to the odds ratios and was validated.</p><p><strong>Results: </strong>On MRI, significantly more patients in the HS group (n=49) than the CD group (n=74) had subcutaneous tunnels (35% vs 4%; P<.001), soft-tissue inflammation of subcutaneous tissue and skin (35% vs 5%; P<.001), and inguinal lymphadenopathy (65% vs 45%; P=.02). Significantly more patients in the CD group than the HS group had transsphincteric fistula (64% vs 35%; P=.002), intersphincteric fistula (58% vs 29%; P=.001), mesorectal lymphadenopathy (26% vs 4%; P=.002), and rectal inflammation (32% vs 12%; P=.01). The proposed MRI scoring system for distinguishing HS from CD had a sensitivity of 0.77, specificity of 0.80, and area under the curve of 0.84.</p><p><strong>Conclusion: </strong>MRI may be a valuable tool in distinguishing perianal draining tunnels in HS from fistulizing perianal CD. The MRI scoring system we created could help in the clinical decision-making process. Combining MRI with other investigational and clinical findings may improve diagnostic accuracy for these challenging perianal diseases.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-20"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Martian Dermatology: A Narrative Review of Dermatoses for Future Explorers.","authors":"Ryan Scheinkman, Rahul Aggarwal, Eran Gwillim, Fulvia Verde, Keyvan Nouri","doi":"10.1159/000547408","DOIUrl":"https://doi.org/10.1159/000547408","url":null,"abstract":"<p><strong>Background: </strong>The complex interplay of the Martian environment, equipment, and difficulties of delivering care present unique challenges for dermatology.</p><p><strong>Summary: </strong>In this review we sought to provide an overview of dermatological challenges associated with future human exploration of the surface of Mars and provide information on preventative strategies and treatment methods. Sources relevant to Martian dermatology were collated from a PubMed and Google scholar relevant to dermatological conditions associated with Martian exploration. Dermatoses from equipment and environmental factors (e.g. radiation, regolith, decompression from low pressure) were reviewed for pathology, treatment, and prevention.</p><p><strong>Key messages: </strong>Dermatologists can help inform human factors engineering solutions for mission design (e.g. space suit considerations for skin), provide preventative guidance, inform diagnosis and treatment protocols, and provide remote consoling for patients through tele-dermatology as skin health concerns arise.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-16"},"PeriodicalIF":3.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical drug treatment of rosacea in Switzerland: A descriptive study using Swiss claims data.","authors":"Tamino Zappalà, Alexander A Navarini, Carola A Huber, Christoph R Meier, Julia Spoendlin","doi":"10.1159/000547337","DOIUrl":"https://doi.org/10.1159/000547337","url":null,"abstract":"<p><strong>Introduction: </strong>Rosacea, a chronic inflammatory condition primarily affecting the skin of the face, has long been an area of interest for pharmaceutical advancements. In Switzerland, metronidazole was the only first-line topical rosacea medication (TRM), until brimonidine was licensed in 2014 and ivermectin in 2016. We aimed to evaluate the use of TRM between 2012 and 2023 in Switzerland.</p><p><strong>Methods: </strong>We used claims data from the Swiss health insurance 'Helsana Group' between 2012 and 2023 (study period). We quantified monthly number of claims for each TRM per 10,000 insured persons, as well as overall and annual prevalence of patients treated with TRM in Switzerland, stratified by age (≥/<50 y) and sex in 2023. Among all continuously enrolled persons (period prevalence) and persons insured during the entire calendar year (annual prevalence), we identified all persons with at least one claim of either topical metronidazole, brimonidine, or ivermectin. We additionally evaluated the proportion of patients with only one, two to five, or more than five claims for any TRM during the study period, and stratified patients by number of different TRM claimed within the same calendar year. Lastly, we evaluated the proportion of patients with comedications of interest (i.e. class 1 or 2 topical corticosteroids or oral tetracycline-antibiotics) within the same calendar year.</p><p><strong>Results: </strong>Metronidazole was the most frequently claimed TRM in Switzerland during the study period (5.1 claims / 10,000 / month) but decreased by 11% since market introduction of ivermectin in 2016. Ivermectin continuously increased, accounting for 43% of all TRM claims in 2023 (4.0 claims / 10,000 / month). Overall prevalence of patients treated with TRM was 4.7%, whereas annual prevalence was lower but increased from 0.4% (2012) to 0.7% (2023); it was highest among women ≥50 years of age (1.4%). Of all patients treated with TRM, 54% had only one claim for any TRM, while 36% had between two and five claims, mostly monotherapy of metronidazole (52%) or ivermectin (36%). Throughout the study period, approximately 7% had at least one claim for any topical corticosteroid within the same calendar year. In total, 16% claimed oral tetracycline-antibiotics (80% doxycycline), which slightly decreased since 2017.</p><p><strong>Conclusion: </strong>The discrepancy between annual and overall prevalence suggests that many patients treated with TRM receive intermittent therapy. Despite the decline in use, metronidazole remains the most frequently used TRM in Switzerland, but use of ivermectin increased continuously. The slight decrease in tetracycline-antibiotics among patients treated with TRM after 2017 might reflect efficacy of ivermectin.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-16"},"PeriodicalIF":3.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidradenitis Suppurativa Prevalence in Santiago, Chile.","authors":"Francisco Reyes-Baraona, Carlos Matas, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000538423","DOIUrl":"10.1159/000538423","url":null,"abstract":"<p><strong>Background: </strong>The worldwide prevalence of hidradenitis suppurativa (HS) still remains unknown. In Latin America, there are scarce data regarding the prevalence of HS and in Chile, we do not have information about it. The aim of this study was to estimate the prevalence of HS in Santiago, Chile.</p><p><strong>Methods: </strong>This study is part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative. It was a multicenter center study in secondary care in Santiago, Chile. The inclusion criteria were apparently healthy adults accompanying a patient to the health center that were approached in the waiting room of internal medicine or pediatrics departments. A previously validated screening questionnaire for HS was used. Screen-positive and randomly selected screen-negative participants were clinically examined.</p><p><strong>Results: </strong>500 participants were included. The prevalence of HS in the sample was 2.4% (12/500; 95% CI: 1.4%-4.1%). In the HS group, all were female (100%; p = 0.019), with a median age of 35.5 years (p = 0.089) and 25% were smokers (p = 1). Body mass index (BMI) of patients with HS was significant higher than non-HS patients (30.9 kg/m2 and 28.1 kg/m2, respectively; p = 0.028). Axilla and groin were the predominant sites of affection (58.3% each one). 75% of HS patients were classified as Hurley stage I and 25% as Hurley stage II.</p><p><strong>Conclusion: </strong>The estimated prevalence of HS in Santiago of Chile was 2.4%, which is high compared to other previous reports worldwide but similar to other countries participating in the GHiSA initiative. In our study, we only had female patients with HS, suggesting a clear predominance of women suffering HS in Chile. A high BMI appears to be a risk factor for HS in our population. The screening questionnaire for HS is a suitable tool for population surveys.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Bucharest, Romania.","authors":"Elena-Daniela Serban, Maria-Magdalena Constantin, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000540423","DOIUrl":"10.1159/000540423","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa is a chronic inflammatory disease of the apocrine gland-bearing areas frequently misdiagnosed or underdiagnosed. Its true prevalence is still unknown and there is an ongoing interest in this matter. The current study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative that is actively involved in better understanding the epidemiological characteristics of HS.</p><p><strong>Methods: </strong>This study was a multicenter study in 2 tertiary care hospitals in Bucharest. After obtaining consent, data from 796 healthy accompanying adults were included. A validated screening questionnaire was used before the clinical examination of the screening-positive and randomly selected screening-negative participants, respectively.</p><p><strong>Results: </strong>The prevalence of hidradenitis suppurativa in Bucharest, Romania was 0.75% (95% confidence interval: [0.35%-1.63%]).</p><p><strong>Conclusion: </strong>There aren't any data available regarding the prevalence of hidradenitis suppurativa in Romania and the current report is the first paper addressing the prevalence of HS in the capital of Romania, Bucharest.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant Extracts in Acne Management: a narrative review.","authors":"Mathieu Leti, Lucile Garidou, Stéphane V Cuisiat, Aline Stennevin, Gautier Doat, Céline Mias","doi":"10.1159/000547149","DOIUrl":"https://doi.org/10.1159/000547149","url":null,"abstract":"<p><strong>Background: </strong>Acne is a chronic inflammatory skin disease associated with impaired pilosebaceous unit function leading to the development of noninflammatory and inflammatory lesions and, in some cases, persistent post-inflammatory erythema, hyperpigmentation and scarring. Acne pathophysiology is complex, involving altered sebum production and composition, abnormal keratinization, microbiome dysbiosis, and skin inflammation. Conventional therapies, such as topical retinoids, antibiotics and benzoyl peroxide, are the first-line treatments for mild-to-moderate acne, but antibiotic resistance and local adverse effects can have a negative impact on therapeutic outcomes, leading to a growing interest in alternative strategies for disease management. The use of dermocosmetics is increasingly being recognized as a useful strategy to improve treatment outcomes and patient adherence. In particular, there has been a recent increase in research aiming to identify natural plant-based ingredients with properties that target the multiple pathogenic mechanisms involved in acne, but which have less impact on skin barrier function.</p><p><strong>Summary: </strong>This review provides a summary of the anti-acne properties of the most well-characterized plant extracts and phytocompounds used in dermocosmetic anti-acne products, based on insights gained from in vitro, ex vivo and in vivo studies. Evidence gained from clinical trials evaluating the effectiveness and safety of topical formulations containing these herbal ingredients is also presented. Finally, several less well-characterized herbal extracts and phytocompounds with promising anti-acne properties are described.</p><p><strong>Key messages: </strong>Although research is ongoing for many of the anti-acne herbal ingredients identified so far, this review highlights the effectiveness of topical plant-based formulations for reducing lesion counts and disease severity in acne patients, as well as the rebalancing effects of herbal ingredients on sebum composition, microbial diversity, and pilosebaceous unit cell differentiation. Taken together with the antibiofilm, anti-inflammatory, antioxidant, and skin barrier repair properties demonstrated for many of these extracts, current evidence suggests that dermocosmetics with plant-based ingredients show great promise for acne management, either as monotherapies, maintenance treatments, or in combination with conventional drugs.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-51"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Antalya, Türkiye.","authors":"Erkan Alpsoy, Sena Akanlar, Samir Naghiyev, Dorra Bouazzi, Caner Vardar, Oğuz Yılmaz, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000542480","DOIUrl":"10.1159/000542480","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) prevalence studies show considerable regional discrepancies due to various methodological and/or ethnic factors. The prevalence of HS in Türkiye has yet to be examined. This study aimed to assess the HS prevalence with a validated screening questionnaire in Antalya-Türkiye as part of the major project to determine the global prevalence of HS.</p><p><strong>Methods: </strong>This single-center, cross-sectional study in a tertiary health institution was conducted among healthy volunteer adults accompanying patients in the internal medicine outpatient clinics of Akdeniz University between July and November 2022.</p><p><strong>Results: </strong>The study included 1,012 participants, 544 females, and 468 males. Seven participants (4 females and 3 males, median age 44.0 [IQR 40.5-54.5] years old) had HS, and the prevalence was 0.69% (95% confidence interval [0.33%-1.4%]). The proportion of HS at an early stage was higher than the rate previously reported from the same center in a registry research (Hurley I, 28.57% vs 16%). The examination of 110 screen-negative participants did not reveal any HS. There was no difference between HS patients and non-HS participants regarding gender, age, BMI, and daily smoking rate.</p><p><strong>Conclusion: </strong>HS prevalence in Antalya seems compatible with the global prevalence of the disease. This study did not confirm the male dominance observed in Türkiye in earlier studies. The HS patients diagnosed in the study represent a milder spectrum of the disease.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hidradenitis Suppurativa in Hospital Kuala Lumpur, Malaysia: A Cross-Sectional Study.","authors":"Moonyza Akmal Ahmad Kamil, Azahirafairud Abdul Rahim, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec","doi":"10.1159/000539397","DOIUrl":"10.1159/000539397","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a painful, chronic, recurring, debilitating, inflammatory skin disease affecting the areas rich in apocrine glands, with typical lesions (abscesses, nodules, discharging sinuses, and scars) and distribution (intertriginous areas). The prevalence of HS varies across geographical locality with lower rates reported in Asia.</p><p><strong>Methods: </strong>A cross-sectional, descriptive study, involving 500 consecutive healthy adults in Hospital Kuala Lumpur (HKL), was done from December 2022 to April 2023, to estimate the prevalence of HS in HKL, via a validated questionnaire. We included healthy hospital staff and those accompanying patients in the Department of Medicine. Consented participants would answer the screening questionnaire for HS, as well as the socio-demographic data questionnaire. The screened-positive participants were evaluated by a dermatologist to confirm the diagnosis of HS and to take clinical photos.</p><p><strong>Results: </strong>Ten participants were screened-positive for HS, but only 7 were confirmed cases. The prevalence of this study was 7/500 (1.4%). Majority had mild diseases (71% Hurley stage 1, 29% Hurley stage 2). HS was more prevalent among males (n = 4), lower education level (n = 4), and Chinese ethnicity (n = 3). There was no significant difference among the HS participants when compared to non-HS participants based on their age, gender, education level, income status, BMI, or smoking status (p > 0.05).</p><p><strong>Conclusion: </strong>HS is a complex disease with multifactorial elements to consider in its pathogenesis. The availability for early detection of mild HS disease, via a validated screening questionnaire, may change the paradigm of management of HS in the future.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}